Short Interest in Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Decreases By 91.5%

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the recipient of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 4,700 shares, a decline of 91.5% from the January 31st total of 55,100 shares. Based on an average daily trading volume, of 56,600 shares, the short-interest ratio is currently 0.1 days.

Enzon Pharmaceuticals Stock Up 2.7 %

Shares of ENZN traded up $0.00 during trading on Thursday, reaching $0.10. The company’s stock had a trading volume of 5,168 shares, compared to its average volume of 109,502. Enzon Pharmaceuticals has a twelve month low of $0.06 and a twelve month high of $0.24. The company has a market cap of $7.35 million, a price-to-earnings ratio of 9.91 and a beta of 0.26. The company has a fifty day moving average of $0.15 and a two-hundred day moving average of $0.13.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.